success stories
- Filter:
- All
- #
- a
- b
- c
- d
- e
- f
- g
- h
- i
- j
- k
- l
- m
- n
- o
- p
- q
- r
- s
- t
- u
- v
- w
- x
- y
- z
Agilux Laboratories
Acquired by Charles River Laboratories
Learn moreAlpha-Beta Technology, Inc.
Acquisition
Alpha-Beta was the second ever startup company to enter the MBI incubator. The company reached a peak headcount of 220 employees and peak market capitalization of $350 million, before being sold in 1999. Products developed by the startup are now marketed as Wellmune by Kerry, a global health and nutrition company.
Learn moreAntigen Express, Inc
Acquired by Generex
Learn moreAvatar Pharmaceuticals
Acquired by Vertex Pharmaceuticals
Learn moreAverica Discovery Services Inc
Acquired by NeoPharm
Learn moreBeckman Coulter
Acquired by Danaher
Learn moreBiocytogen, LLC
IPO, $335M+
Learn moreBioflash Partners, LLC
Acquired by Repligen
Learn moreBiomere
Acquired by JOINN Laboratories Co. Ltd.
Learn moreBlue Sky Biotech, Inc
Acquired by Curia
Learn moreColey Pharmaceutical Group, Inc
Acquired by Pfizer
Learn moreConvergent Dental
$115M+ raised, commercialized product
Learn moreCreoptix
Acquired by Malvern Panalytical
Learn moreDXA Resource Group, Inc.
Founded in 2002, DRG recognized the need for cost-effective and responsive DXA (Dual- Emission X-Ray Absorptiometry) clinical quality assurance, project management and data management services to support drug development.
Learn moreECI Biotech
Acquired by Alira Health
Learn moreEden Research
Learn moreGQ Life Sciences
Acquired by Aptean
Learn moreHSRL, Inc.
Acquired by StageBio
Learn moreIntelligent Bio-Systems
Acquired by Qiagen
Learn moreInvetx
IPO, $80M+
Learn moreiVexSol
Series A
Learn moreNyla Laboratories
Acquired
Learn morePhio Pharmaceuticals
IPO
Phio's focus is centered on the application of self-delivering RNAi therapies in the field of immuno-oncology. Our INTASYL technology is the only self-delivering siRNA technology focused on immuno-oncology. INTASYL is designed to silence specific genes that are implicated in the proliferation of solid cancer tumors.
Learn moreSpring Bank Pharmaceuticals
Acquired by F-Star Therapeutics, Inc.
Learn moreT2 Biosystems
IPO
Learn moreTargeted Pharmaceuticals
Acquired by Tetra Bio-Pharma
Learn moreTarpon Biosystems, Inc
Tech Acquisition by Pall
Learn moreTransCode Therapeutics
IPO, $7M
Learn moreViaCell, Inc
IPO and Acquired by Perkin Elmer
Learn moreVivo Path LLC
Acquired by Charles River Laboratories
Learn more